130 related articles for article (PubMed ID: 29649904)
1. Economic burden of treatment failure in chronic lymphocytic leukemia patients.
Wang S; Lafeuille MH; Lefebvre P; Romdhani H; Emond B; Senbetta M
Curr Med Res Opin; 2018 Jun; 34(6):1135-1142. PubMed ID: 29649904
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
3. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
4. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
[TBL] [Abstract][Full Text] [Related]
5. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States.
Kabadi SM; Goyal RK; Nagar SP; Kaye JA; Davis KL
Cancer Med; 2019 Jul; 8(8):3803-3810. PubMed ID: 31144473
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
Müller D; Fischer K; Kaiser P; Eichhorst B; Walshe R; Reiser M; Kellermann L; Borsi L; Civello D; Mensch A; Bahlo J; Hallek M; Stock S; Fingerle-Rowson G
Leuk Lymphoma; 2016 May; 57(5):1130-9. PubMed ID: 26584689
[TBL] [Abstract][Full Text] [Related]
9. Chronic lymphocytic leukemia: economic burden and quality of life: literature review.
Stephens JM; Gramegna P; Laskin B; Botteman MF; Pashos CL
Am J Ther; 2005; 12(5):460-6. PubMed ID: 16148431
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
Casado LF; Hernández JÁ; Jarque I; Echave M; Casado MA; Castro A
Eur J Haematol; 2018 Mar; 100(3):264-272. PubMed ID: 29226472
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
14. Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.
Lafeuille MH; Vekeman F; Wang ST; Kerrigan M; Menditto L; Duh MS
Leuk Lymphoma; 2012 Jun; 53(6):1146-54. PubMed ID: 22111902
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
[TBL] [Abstract][Full Text] [Related]
16. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
[TBL] [Abstract][Full Text] [Related]
17. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
18. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
19. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Hillmen P
Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
